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The hepatocyte growth factor receptor (HGFR, c-Met or Met) is a receptor tyrosine kinase that is involved
in embryogenesis, tissue regeneration and wound healing. Abnormal activation of this proto-oncogene
product is implicated in the development, progression and metastasis of many cancers. Current thera-
pies directed against Met, such as ligand- or, dimerization-blocking antibodies or kinase inhibitors,
reduce tumor growth but hardly eradicate the tumor. In order to improve anti-Met therapy, we have
designed a drug delivery system consisting of crosslinked albumin nanoparticles decorated with newly
selected anti-Met nanobodies (anti-Met-NANAPs). The anti-Met NANAPs bound speciﬁcally to and were
speciﬁcally taken up by Met-expressing cells and transported to lysosomes for degradation. Treatment of
tumor cells with anti-Met NANAPs also resulted in downregulation of the total Met protein. This study
shows that anti-Met NANAPs offer a potential system for lysosomal delivery of drugs into Met-positive
tumor cells.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The hepatocyte growth factor (HGF) receptor (HGFR, c-Met or
Met) is a receptor tyrosine kinase (RTK) that is primarily expressed
on epithelial cells. HGF is the only known, high afﬁnity ligand for
this receptor [1]. Binding of HGF to Met activates the receptor,
resulting in tyrosine phosphorylation of the receptor and the acti-
vation of several downstream signal transduction pathways such as
the MAPK-, STAT- and PI3kinase/Akt-pathway [1e4]. Met/HGF
signaling is important for embryogenesis and also for tissue
regeneration and wound healing in the adult life [5e7]. Deregu-
lated Met signaling is implicated in the development, progression
andmetastasis of awide variety of human cancers [8,9]. This can be
due to mutational activation, receptor/ligand overexpression,
autocrine activation or ligand-independent activation of Met. Mett Biology, Science Faculty,
e Netherlands. Tel.: þ31 30
gen en Henegouwen).
nds.
All rights reserved.is therefore an attractive target for anti-cancer therapy and several
agents interfering with the Met/HGF pathway are under develop-
ment such as Met/HGF signaling small molecule inhibitors, anti-
bodies and decoy receptors [10,11]. Anti-Met therapies can be
further augmented by combining them with chemotherapeutic
drugs, especially when these are combined in a targeted drug de-
livery system [12].
Like most RTKs, ligand binding and activation of the Met tyro-
sine kinase initiates internalization of the receptoreligand com-
plexes, which is followed by intracellular trafﬁcking and
degradation of both receptor and ligand in lysosomes [11e15]. This
internalization and lysosomal trafﬁcking can be used for targeted
delivery and release of drugs inside tumor cells. Previously, we
designed anti-EGFR Nanobody-Albumin Nanoparticles (NANAPs),
which are albumin-based nanoparticles decorated with nano-
bodies that target the epidermal growth factor receptor (EGFR).
NANAPs were shown to bind to and internalize into EGFR-
expressing cells and were found to be suitable for targeted de-
livery of anti-cancer drugs into cells [16].
A nanobody (or VHH) is the antigen-binding domain of heavy-
chain-only antibodies found in members of the cameilidae family.
Despite their small (w15 kDa) size, their binding afﬁnity is similar
R. Heukers et al. / Biomaterials 35 (2014) 601e610602to that of monoclonal antibodies [17]. Due to their small size and
less complex structure nanobodies can be easily produced in pro-
karyotic systems giving them advantage over monoclonal anti-
bodies or antibody fragments [18]. Nanobody-coupled liposomal
and polymeric nanoparticles have already been shown to induce
tumor regression in mice bearing head and neck squamous carci-
noma tumors [19,20].
In this study we aimed to develop albumin nanoparticles that
speciﬁcally target the Met receptor. We hypothesized that the
speciﬁc uptake and lysosomal trafﬁcking of anti-Met albumin
nanoparticles would stimulate Met downregulation and allow
intracellular delivery of nanoparticles into Met expressing cancer
cells.
2. Materials and methods
2.1. Cell culture and cell lines
The human ovarian carcinoma cell line TOV-112D (cat nr. CRL-11731), human
lung carcinoma cell line A549 (cat.nr. CCL-185) and the human epidermoid squa-
mous carcinoma cell line A431 (cat. nr. CRL-1555) were all obtained from American
Tissue Culture Collection (ATCC, LGC Standards GmbH, Wesel, Germany) and the
human gastric cancer cell line MKN45 (cat. nr. ACC-409) was obtained from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig,
Germany). TOV-112D and A431 cells were cultured in Dulbecco’s Modiﬁcation of
Eagle Medium (DMEM: Gibco, Invitrogen, Breda, The Netherlands) supplemented
with 100 units/ml streptomycin, 0.1 mg/ml penicillin, 2 mM L-glutamine and 10%
fetal calf serum (FCS) at 37C and 5% CO2. MKN45 cells were cultured in RPMI 1640
(Life Technologies Inc., Invitrogen) supplemented with 100 units/ml streptomycin,
0.1 mg/ml penicillin, 2 mM L-glutamine and 20% FCS. A549 cells were cultured in
Ham’s F12 (Life Technologies, Inc., Invitrogen) supplemented with streptomycin,
penicillin, L-glutamine and 10% FCS under the previously mentioned conditions. Met
expression of cells seeded for one or two days was determined by western blotting
using mouse-anti-HGFR (MAB3581, R&D Systems Europe Ltd, Abingdon, UK) fol-
lowed by goat-anti-mouseAlexa488 (Invitrogen) incubation. For the generation of the
stable TOV þ Met cell line, human Met-encoding cDNA (kindly provided by Dr.
Morag Park, McGill University, Montreal, Canada) was ﬁrst transferred from the pXM
vector into a pMX-IRES-Zeo vector (generated from the pMX-SupF vector kindly
provided by prof. Garry P. Nolan, Stanford University School of Medicine, Stanford,
California, USA) via XhoI-XhoI digestion (Thermo Scientiﬁc, Breda, The Netherlands)
and ligation (T4 ligase, Promega, Madison, USA). TOV-112D cells were transfected
with this pMX-Met-IRES-Zeo using Fugene HD (Roche, Mannheim, Germany) and
grown under selection pressure using 200 mg/ml of Zeocin (Invitrogen) for 8 weeks.
Single clones were tested for Met-expression by western blotting.
2.2. Nanobody selection
Nanobodies directed against Met were selected using phage display technology
from a phage antibody library that was made from Llama Glama immunized with
A431 membrane vesicles, as previously described [21]. For selections, Maxisorp 96-
wells plates (Nunc, Roskilde, Denmark) were coated overnight with rabbit-anti-hIgG
in PBS (1:2000, Dako, Glostrup, Denmark) at 4C. Next day, non-speciﬁc binding was
blocked with 2% skimmed milk (Marvel) in PBS (MPBS) for an hour at RT. Subse-
quently, 1 mg of Met-Fc fusion protein diluted in MPBS (R&D systems) per well was
captured for 1 h at room temperature (RT). After three washes with PBS, captured
antigen was incubated with phages (blocked in 2% MPBS) for 2 h at RT. After
washing, bound phages were detached by 100 mM triethylamine (TEA) elution. For
phage ELISA, Maxisorp plates were coated with rabbit-anti-hIgG as described above
and 50 ng/well of Met ectodomain-Fc fusion protein (R&D Systems) was captured for
1 h at RT in 2% MPBS. Single clone phages were incubated for 2 h at RT, washed
extensively and bound phage was detected with mouse-anti-M13HRP (1:10,000),
followed by o-phenylenediamine (OPD) development. The reaction was stopped by
the addition of 3M H2SO4 and OD was read at 450 nm. The cDNAs of the selected
clones were sequenced and then re-cloned into a pET28a vector containing C-ter-
minal Myc-6-His tags and which allows the puriﬁcation of nanobodies from the
periplasmic space of E.coli.
2.3. Production and puriﬁcation of nanobodies
Nanobodies were produced as described before [16], but with minor modiﬁca-
tions. Brieﬂy, E. coli BL-21 Codon Plus (DE3)-RIL (Agilent Technologies Inc., Santa
Clara, CA, USA) cells were transformed with pET28-derived nanobody-encoding
plasmid and a single antibiotic-resistant colony was picked. Production was per-
formed by growing these bacteria in 2xTY medium containing 2% (w/v) glucose and
100 mg/ml ampicillin at 37C overnight. Four hundred milliliters of 2xTY medium
(supplemented with 100 mg/ml ampicillin and 0.2% (w/v) glucose) was inoculated
with the bacteria from the overnight culture with an OD600 of 0.1. This bacterial
culture was subsequently incubated at 37 C at 250 rpm until it reached an OD600 of0.6. Subsequently, 0.5 mM IPTG was added to the bacterial culture to induce nano-
body expression and the culture was further incubated at 37C for 3.5 h. After 3.5 h,
cells were spun down (5000 rpm, 15 min, 4C) and the obtained pellet was stored
over night at 20C. The following day, periplasmic fractions were made by incu-
bating the pellet in 6.4 ml ice cold TES (200 mM TriseHCl, 0.5 mM EDTA, 500 mM
sucrose, pH 8.0). To this suspension, 10 ml of diluted ice cold TES (1:3 in water) was
added and incubated on ice for 30 min. The bacteria were spun down at 4 C for
15 min at 5000 rpm and the supernatant was collected. The pellet was resuspended
in 10ml ice cold TES, 120 ml 1 M MgSO4 was added and themixture was incubated on
ice for 30 min. The suspension was spun down at 4 C for 15 min at 5000 rpm and
the supernatant containing the nanobody was added to the previously collected
supernatant. The his-tagged nanobodies were puriﬁed by means of immobilized
metal ion afﬁnity chromatography (IMAC) on TALON resin (Clontech, Palo Alto, CA,
USA) according to the manufacturer’s protocol (Batch/Gravity-Flow), except 50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0 was used for all washing steps and
elutionwas performedwith the samewash buffer but containing 300mM imidazole,
pH 8.0 buffer. Imidazole was removed by means of dialysis against PBS overnight at
4C. Finally, protein fractions and purity were analyzed by SDS polyacrylamide gel
electrophoresis (SDS-PAGE). Protein concentrations were determined using a Micro
BCA assay (ThermoScientiﬁc).
2.4. FACS analysis
For FACS analysis of binding of the anti-Met nanobodies, Met-expressing A431
cells were trypsinized, blocked and incubated with anti-Met VHHs (developed in
house) or EGF-Alexa488 (Invitrogen) on ice for 2 h. The cells were washed three times
with PBS and ﬁxed in 4% paraformaldehyde (PFA). Auto-ﬂuorescence was quenched
with 100 mM glycine in PBS for 15min and VHHs were detected with Prot-G puriﬁed
rabbit-anti-VHH (developed in house), followed by goat-anti-rabbitAlexa488 (Invi-
trogen) incubation. FACS analysis was performed on a BD analyzer (BD Biosciences,
Breda, The Netherlands).
2.5. Binding and afﬁnity determination of nanobodies
TOV-112D, TOV þ Met (1.5  104 per well) or MKN45 cells (6  104 per well)
were seeded in a 96-wells plates (Nunc) one day before the assay. The cells were pre-
incubated with binding medium (2% BSA in CO2-independent medium (Gibco) for
10 min on ice after which the cells were incubated in binding medium supple-
mented with or without nanobodies (0.005e1000 nM) for 2 h on ice. After three
washes with ice cold PBS, cells were ﬁxed in 4% PFA and ﬁxative was subsequently
quenched with 100 mM glycine in PBS for 15 min. Bound nanobody was detected
with rabbit-anti-VHH (1:1000) in PBS containing 2% BSA (PBA) followed by goat-
anti-rabbit IRDye800CW (Li-COR Biosciences, UK, 1:500 in PBA) incubation for 1 h
at RT each. Finally, cells were washed twice with PBA and ﬂuorescence was
measured using the Odyssey Infrared Imager. Binding afﬁnity (KD) for one site
speciﬁc binding was determined by curve ﬁtting using GraphPad Prism 5.02 for
Windows (GraphPad Software, San Diego, CA).
2.6. HGF competition
HGF was labeled with 125I (Perkin Elmer, USA) according to the IODO-GEN
(SigmaeAldrich) method as described previously [22]. The speciﬁc activity of I125-
HGF wasmeasured atw30,000 CPM/mg. Maxisorp 96-well ELISA plates (Nunc) were
coated with rabbit anti-human IgG (Dako, Glostrup, Denmark; 4 mg/mL in PBS). The
next day, wells were washed with PBS, blocked with 1% MPBS and subsequently
incubated with 0.1 mg/mL of Met-ECD-Fc. After washing with PBS, the wells were
incubatedwith 1 nM of 125I-HGF in the presence or absence of 1000 nM of nanobodies
for 1 h. Wells were washed four times with PBS and bound I125-HGF was collected
after 5 min incubation with 1 M NaOH; radioactivity was measured using a gamma
counter (WallacWizard, Perkin Elmer). Results were analyzed using GraphPad Prism
version 5.02 for Windows, GraphPad Software (San Diego, CA).
2.7. Preparation of albumin nanoparticles
Nanoparticles were prepared by the ethanolic desolvation technique as
described previously [16,23] with minor modiﬁcations. Brieﬂy, human serum al-
bumin (HSA, 50 mg/ml) was dissolved in deionized water after which the pH was
adjusted to 8.3 by addition of 0.1 M NaOH and the solution was ﬁltered through a
0.2 mm ﬁlter (Minisart syringe ﬁlters, Sartorius-stedim, Germany). Nanoparticles
were formed by adding 92% ethanol drop wise under constant stirring. The formed
particles were crosslinked with 8% glutaraldehyde (GA) overnight at RT. The
nanoparticles were puriﬁed by centrifugation ﬁrst at 1000 g for 5 min (pellet dis-
carded, supernatant collected) and three times at 45,000 g for 1 h at 4C in
deionized water. Nanoparticles were stored in deionized water at 4C. Nanoparticle
yield was determined by measuring the dry weight by thermogravimetric analysis.
The absence of soluble albumin and multimers was checked by SDS-PAGE (4e12%
crosslinked, Invitrogen) under reducing conditions followed by Coomassie blue
staining. For enabling detection of nanoparticles in ﬂuorescence microscopy or
quantiﬁcation on the Odyssey Infrared Imager, nanoparticles were labeled with
either Alexa488-NHS (Invitrogen) or IRDye800CW-NHS (Li-COR) as described
before [16].
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Fig. 1. The three selected anti-Met nanobodies bind Met with low nM afﬁnities on cells. A) Binding of anti-Met nanobody C3, F5 and G2 to A431 cells measured by FACS and
compared to untreated cells (red). EGF-Alexa488 was used as a positive control for binding. B) Speciﬁc binding of C3, F5 and G2 to TOV þMET cells. R2 (non-relevant nanobody) was
used as a negative control. C) Binding curves and afﬁnities (KD) of C3, F5 and G2 on high Met-expressing cell line MKN45. D) Binding competition of 125I-labeled HGF by anti-Met
nanobodies. Maxisorp plates were coated with Met ectodomain and binding of 1 nM of 125I-labeled HGF in the presence or absence of 1000 nM of nanobodies. Error bars represent
SEM, where n > 4. * indicates p < 0.001 as determined by t-test.
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The anti-Met nanobody G2 was modiﬁed with either a 2-,4- or 8-fold molar
excess of N-succinimidyl-S-acetylthioacetate (SATA) (Pierce Biotechnology, Rock-
ford, IL, USA) as described in Ref. [19]. Brieﬂy, the introduced sulfhydryl groups were
deacetylated for 30 min at RT prior to addition of SATA-G2 to freshly prepared
maleimidiyl-PEG nanoparticles. 18 mg of nanoparticles (4 mg/ml) were reacted with
14 mg of NHS-PEG3500-maleimide (15:1, mol/mol, PEG:HSA) in 0.1 M phosphate
buffer (PB), pH 8 for 1 h at RT on a roller bench. PEGylated nanoparticles were
collected by centrifugation and resuspended in 0.1 M PB, pH 7 and immediately
reacted with SATA-modiﬁed G2 (0.1 mg G2/mg nanoparticle, 0.4 nmol G2/nmol
albumin) for 2 h at RT. G2-PEG-NP were characterized for G2 coupling with dot-blot
immunodetection of G2 [16].
2.9. Characterization of nanoparticles
Size distribution and polydispersity of the nanoparticles were determined by
dynamic light scattering (DLS) on a Malvern ALV CGS-3 (Malvern Instruments,
Malvern, UK) containing a He\Ne laser source (l ¼ 632.8 nm, 22 mWoutput power)
under an angle of 90 . The zeta potential of the nanoparticles was determined using
aMalvern zetasizer Nano-Z (Malvern Instruments, Malvern, UK). Themeasurements
were performed in 5 mM PB, pH 7.4 at 25 C.
2.10. G2-SATA characterization by capillary electrophoresis
The degree of SATA labeling on G2 was measured by means of capillary elec-
trophoresis (CE) experiments which were carried out on a P/ACE MDQ CE in-
strument (Beckman Coulter, Brea, CA, USA). The separation voltage was 30 kV and
the capillary temperature was 20 C. Fused-silica capillaries (total length, 85 cm;
inner diameter, 50 mm, outer diameter, 360 mm) were obtained from Polymicro
(Phoenix, AZ, USA). The capillaries were coatedwith a triple layer Polybrene-dextran
sulfate-Polybrene (PB-DS-PB) coating as described previously [24e26]. The back-
ground electrolyte (BGE) was 100 mM acetic acid (pH 2.8). Nanobody was hydro-
dynamically injected for 14 s at 1 psi (equal to 1% of the capillary volume). MS
detectionwas performed using a micrOTOF-Q orthogonal-accelerated time-of-ﬂight
(TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany). Transfer parameters
were optimized by direct infusion of an electrospray ionization (ESI) tuning mix
(Agilent Technologies, Waldbronn, Germany). CE-MS coupling was realized by a co-
axial sheath liquid interface (Agilent Technologies, Waldbronn, Germany). A sheath
liquid of isopropanol-BGE (75/25, v/v) at a ﬂow rate of 3 mL/min was used. Thefollowing optimized spray conditions were used: dry gas temperature, 180C; ni-
trogen ﬂow, 4 L/min; and nebulizer pressure, 0.4 bar. Electrospray in positive ioni-
zation mode was achieved using an ESI voltage of 4.5 kV. CE-MS data were
analyzed using Bruker Daltonics DataAnalysis software. For the determination of
peak areas, extracted-ion electropherograms (EIEs) were constructed for the
respective protein species from their most abundant m/z signals ([M þ nH]nþ;
n ¼ 12e15). Protein charge assignment and molecular weight determinations were
performed using the ‘charge deconvolution’ utility of the DataAnalysis software.
2.11. Cellular binding and internalization of nanoparticles
To test the binding of the NANAP’s to Met-expressing cells, TOV-112D,
TOV þ Met, A549 (20.000 cells/well) and MKN45 (60.000 cells/well) were seed
into 96-wells plates (Nunc), one day before the assay. Cells were pre-incubated with
binding medium for 10 min on ice and subsequently incubated with IRDye800-
labeled nanoparticles (0.06e0.5 mg/ml) for 2 h on ice. Cells were washed for
10 min with 2% Marvel in binding medium, followed by PBS, after which binding of
nanoparticles was quantiﬁed with the Odyssey Infrared Imager.
For ﬂuorescence microscopy imaging, the cells were seeded in chamber slide
(Lab-Tek, Nunc) one day before the experiment. Cells were incubated with 0.25 mg/
ml of Alexa488-conjugated nanoparticles in binding medium for 2 h on ice. For
internalization, the nanoparticles were allowed to internalize for 2 h at 37C. Cells
were washed with binding medium and PBS extensively and ﬁxed in 4% PFA. PFA-
induced autoﬂuorescence was quenched by incubation with 100 mM glycine in PBS
for 15 min at RT and slides were mounted using SlowFade (Invitrogen). Fluorescent
pictures were taken using a Zeiss LSM700 confocal microscope (Carl Zeiss Micro-
scopy GmbH, Germany) equipped with and 63 oil immersion objective (NA 1.4).
2.12. Nanoparticle lysosomal degradation assay
Lysosomal processing of nanoparticles was studied with IRdye800-labeled
nanoparticles as described previously [16]. Cells were seeded (200.000 cells/well
for A549 and 600.000 cells/well for MKN45) in 12-well plates (Becton & Dickinson,
Mountain View, CA, USA) one day before the experiment. Cells were pulsed with
0.25 mg/ml IRDye800-labeled nanoparticles for 2 h at 37C. The medium was
replaced by fresh medium supplemented with or without 10 mM of chloroquine (CQ,
an inhibitor of lysosomal degradation, Sigma Aldrich) or lactacystin (LC, an inhibitor
of proteasomal degradation, kindly provided by Dr. Marcel A.G. van der Heijden,
Division of Heart and Lungs, UMC Utrecht, The Netherlands) and cells were
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R. Heukers et al. / Biomaterials 35 (2014) 601e610604incubated for an additional 16 h at 37 C. Cells were washed with PBS and lysed in
30 ml of reducing sample buffer (50 mM TriseHCl, pH 6.8, 10% glycerol, 100 mM DTT,
2% SDS and 0.01% bromophenol blue). IRDye800 peptide fragments were separated
by SDS-PAGE and quantiﬁed using the Odyssey Infrared Imager. Mean and SEM of
the intensity of the peptide bands obtained from three independent experiments
were calculated.
2.13. Phosphorylation and downregulation of Met
Agonistic or antagonistic properties of G2 (1 nM, 1 mM), PEG-NP (0.5 mg/ml) and
G2-PEG-NP (0.5 mg/ml) were studied using A549 andMKN45 cells that were seeded
in 12 well plates (240.000 cells/well) and incubated overnight in 0.1% FBS. Formu-
lations were diluted in 0.1% FBS medium and incubated with the cells for 30 min at
4C. Subsequently, 50 ng/ml HGF (R&D system) was added and the cells were
incubated for 10min at 37C. Cells werewashed with PBS two times, lysed with RIPA
buffer (Teknova) supplemented with Halt Protease & Phosphatase Inhibitor
Cocktail (Thermo Scientiﬁc) and lysates were collected. For Met downregulation
experiments, A549 and MKN45 cells (200.000 and 400.000 cells/well) were seeded
in 24 well plates and adhered overnight, followed by incubation with 100 nM G2,
0.5 mg/ml PEG-NP or G2-PEG-NP in (serum-containing) medium for 48 h at 37C.
Next, cells were washed with PBS two times and lysed. The collected fractions were
centrifuged at 15 000 g for 15 min at 4C and the supernatant was collected and
stored at 4C. Quantiﬁcation of total protein content was performed using a Micro
BCA Kit (Thermo Scientiﬁc) and a fraction corresponding to 5 mg protein was loaded
on a reducing SDS-PAGE gel (4e12% crosslinked, Invitrogen). Western Blot analysis
was performed as previously described [16]. Total and phosphorylated Met were
detected by immunoblotting with rabbit anti-phospho-Met (pY1234/pY1235) and
anti-Met antibody (Cell Signaling, 1:1000 diluted) in 5% BSA-TBS-T for 2 h on the
roller bench at RT. Beta-actin rabbit antibody (Cell Signaling, 1:1000 diluted) was
used as a loading control. Anti-rabbit IgG HRP-linked (Cell Signalling, 1:3000
diluted) secondary antibody was added to the membrane and proteins were visu-
alized by chemoluminescence.
2.14. Scratch wound assay
The effect of G2 and G2-PEG-NP on cell migration was assessed by a scratch
wound assay as described by Liang et al. with minor modiﬁcations [27]. Brieﬂy, cells
were seeded in a 48wells plates and allowed to adhere overnight (120.000 cells/well
for MKN45 and 45.000 cells/well for A549). The following day, cells were starved in
0.1% FBS medium for 2 h and a vertical, uninterrupted wound was created in the cell
monolayer using a sterile 200 ml pipette tip. Formulations were diluted in 0.1% FBS
medium and incubated for 24 h. Images of the wounded cell monolayer were taken
using a Nikon Eclipse Te-2000-U microscope (40magniﬁcation) at the start of the
incubations and again after 24 h. The surface of the scratch area (A) was measured
using ImageJ software. Results are expressed as percentages of wound closure for
each well using the formula: 100  [1  (At24/At0)]. Statistical analysis was per-
formed with GraphPad Prism software using a one-way analysis of variance
(ANOVA) followed by Student’s t-test.3. Results
3.1. Selection and characterization of anti-Met nanobodies
To obtain nanobodies against the extracellular domain of Met,
selections were performed from an in-house prepared phage
nanobody library that was constructed using the immunoglobulin
repertoire of peripheral blood lymphocytes of Llama immunized
with vesicles from Met-expressing A431 cells [21]. After a single
round of selection on the Met ectodomain, followed by a non-
speciﬁc elution, binding of Met-speciﬁc clones to the Met ectodo-
main was tested by phage-ELISA. Of all phages that bound Met,
three clones with different CDR sequences were selected (C3, F5
and G2) and these were re-cloned into a bacterial production
vector. Binding of these anti-Met nanobodies to Met-expressing
cells was ﬁrst tested on A431 cells by ﬂuorescence activated cell
sorting (FACS) analysis (Fig. 1A). As compared to the untreated cells
(indicated in red), all three nanobodies showed signiﬁcant binding
to A431 cells. Because A431 cells also express high numbers of
EGFR, EGF-Alexa488 was taken as a control for binding. HGF was
not a proper control for speciﬁc receptor binding, since this growth
factor also interacts with heparin sulfates, which are present in the
plasma membrane of these A431 cells [28].
To test the speciﬁcity of the nanobodies towards Met, we used
Met-positive and Met-negative cell lines. The expression of Met on
TOV-112D cells was ﬁrst tested and these cells were conﬁrmed to be
Met-negative (Fig. S1A). Subsequently, a clone stablyexpressingMet
was obtained by transient transfection and selection for antibiotic
resistance. Stable Met-expression of different clones was deter-
mined by immunoﬂuorescence and the cell line showing highest
Met expression was selected as the Met-positive cell line, indicated
as TOV þ Met (Fig. S1B). All three anti-Met nanobodies showed
signiﬁcant binding to only the TOVþMet cells, but not to TOV-112D
cells, indicating speciﬁcity towards the human Met receptor
(Fig.1B). The control nanobodyR2 (directed at theAzoDyeRR6 [29])
did not signiﬁcantly bind to either cell line. Subsequently, binding of
the nanobodies to Met was further characterized by determining
their afﬁnity (KD) on MKN45 cells, which overexpress Met on their
Table 1
Characteristics of albumin nanoparticles.
Nanoparticles Size (nm) Zeta potential (mV) PDIa
NP 87  9 30  3 0.06  0.02
PEG-NP 106  5 18  2 0.10  0.03
G2-PEG-NPb 102  3 19  4 0.10  0.02
a Polydispersity index.
b 6 nmol G2/mg NP.
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Fig. 3. G2-PEG-NPs bind speciﬁcally to Met-expressing cells. A) TOV-112D, B) TOV þMet, C)
NP. A concentration range of IRDye800-conjugated NANAPs were used for determining level o
NANAPs were used for detection by confocal ﬂuorescence microscopy (right, indicated in g
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with lownanomolar afﬁnities (2.6 0.7 nM for C3, 4.2 0.9 nM for F5
and 1.1  0.2 nM for G2). To test whether the obtained nanobodies
competed for ligand binding, an HGF competition assay was per-
formed. As a control, an excess of unlabeled HGF was able to almost
completely compete off the binding of 125I-labeled HGF from coated
Met ectodomain (Fig. 1D). Similarly, all three anti-Met nanobodies
clearly showed competition with the labeled HGF, while the non-
relevant nanobody R2 did not show any effect.NP-G2
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reen). Nuclei were stained with DAPI (blue). Error bars represent SEM, where n ¼ 3.
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In order to obtain nanoparticles targeting Met-expressing tu-
mors, we decorated these particles with the selected nanobodies.
This coupling was achieved via SATA groups on lysine residues of
the nanobodies and a maleimide-PEG linker on the nanoparticles.
To test whether random SATA modiﬁcations would affect the
integrity of the selected nanobodies, different amounts of SATA
were allowed to react with C3, F5 and G2 and the effect of these
modiﬁcations on binding afﬁnity was studied on MKN45 cells
(Fig. S2A-C). The introduction of SATA moieties to C3 and F5 did
decrease their binding afﬁnity to MKN45 cells by two fold, whereas
G2, even with high modiﬁcation ratios, was not affected (KD of
w1 nM for all degrees of modiﬁcation). The degree of SATA modi-
ﬁcation in G2, the average amount of SATA modiﬁcations per
molecule, was quantiﬁed by capillary electrophoresis followed by
time-of-ﬂight mass spectrometry (CE-TOF-MS) (Fig. 2A). The mo-
lecular weight found for peak 1 (17.6 kDa) corresponded to the
unconjugated G2 nanobody. The subsequent increases in molecular
weight (peak 2e6) corresponded well with the calculated mass of
the introduced SATA groups (116 Da). G2 carrying 1 to 4 SATA
modiﬁcations accounted for more than 90% of the relative peak
area and on average, a conjugation of approximately 2.4 SATA
molecules per G2 nanobody was found.3.3. Preparation and characterization of G2-coupled albumin
nanoparticles
The SATA-modiﬁed G2 nanobody was coupled to the PEGylated
nanoparticles (NP) to generate G2 decorated nanoparticles (G2-PEG-NP). The coupling efﬁciency of SATA-modiﬁed G2 to albumin
nanoparticles was investigated by reacting increasing amounts of
G2 with the PEGylated nanoparticles, followed by dot-blot analysis
of the nanoparticles with anti-VHH antiserum. Nanobody coupling
was found to be saturated at G2:NP ratios of 6 nmol/mg NP and
higher (Fig. 2B). The covalent attachment of G2 to the PEG anchor
was conﬁrmed by SDS-PAGE analysis of G2-PEG-NP, which showed
the absence of unbound G2, indicating complete binding of G2
nanobodies to the nanoparticles (data not shown). Size determi-
nation of the nanoparticles showed that the G2-decorated nano-
particles were approximately 100 nm in size after PEGylation
(polydispersity <0.1) and had a slightly negative zeta potential
of 19 mV (Table 1).3.4. The anti-met NANAPs bind speciﬁcally to Met-expressing cells
The speciﬁcity of the G2-coupled nanoparticles was determined
by studying the binding of IRDye800-conjugated PEG-NP and G2-
PEG-NP to either Met-negative TOV-112D cells or the TOV þ Met
variant (Fig. 3AeB, left). Both non-targeted PEG-NP and targeted
G2-PEG-NP showed some binding to the Met-negative cells. The
linear fashion inwhich this binding was detectedwas considered to
be indicative of non-speciﬁc low-afﬁnity interactions. Importantly,
G2-PEG-NP showed speciﬁc binding to TOV þMet cells with a half-
maximal binding of approximately 0.15 mg/ml. Fluorescence mi-
croscopy imaging with Alexa488-labeled nanoparticles conﬁrmed
speciﬁc binding of G2-PEG-NP to TOV þ Met cells and low back-
ground binding to Met-negative cells (Fig. 3AeB, right). Similar
results with respect to binding speciﬁcity were obtained with the
Met-expressing tumor cell lines, A549 and MKN45. Only G2-PEG-
Fig. 5. G2-PEG-NP internalize speciﬁcally into Met-expressing cells. A) A549 (left) and MKN45 (right) cells were incubated with Alexa488-conugated G2-PEG-NP or PEG-NP for 2 h
at 37 C. B) Cells were incubated as in A and subsequently ﬁxated and permeabilized. Early endosomes were stained with anti-EEA1 antibodies and nuclei were stained with DAPI
(blue).
R. Heukers et al. / Biomaterials 35 (2014) 601e610 607NP showed membrane binding to the Met-expressing tumor cell
lines while untargeted PEG-NP showed only low (background)
binding (Fig. 3CeD).
3.5. NANAPs induce Met phosphorylation but no cell scattering
In order to study whether the observed nanoparticle uptake is
accompanied by receptor activation, their agonistic/antagonistic
properties were determined on A549 cells by western blotting
(Fig. 4A). The G2 nanobody alone did not stimulate Met activity at a
low concentration (1 nM), but at higher concentration (1 mM) the
Met receptor was clearly phosphorylated. As expected, PEG-NP did
not result inMet activation, but the targeted G2-PEG-NP stimulated
Met activity at all concentrations tested (Fig. 4A, left). To test
whether the nanobodies or nanoparticles would have an intrinsic
therapeutic activity by blocking ligand binding, A549 cells were
incubated with G2 or nanoparticles, in the presence and absence of
HGF. None of the formulations blocked HGF-induced phosphory-
lation of Met (Fig. 4A, right). Also in the MKN45 cells, none of the
formulations were able to reduce receptor activation of Met
(Fig. S3). To investigate whether the agonistic property of G2-PEG-
NP as observed by Met activation would have an actual down-
stream effect, we performed a scratch wound assay (Fig. 4B, left).
For this experiment, A549 cells were used, since the constitutive
activation of Met in MKN45 cells make them non-responsive to the
ligand for Met. G2, PEG-NP or G2-PEG-NP did not induce woundclosure, a complete closure of the scratch woundwas only observed
upon treatment with HGF. This means that, even though the G2-
PEG-NP or G2 (only at 1 mM) are able to cause phosphorylation of
Met, this is insufﬁcient to induce cell scattering of A549 cells. A
similar approach was chosen to investigate the downstream
antagonistic effect of the anti-Met nanobodies or nanoparticles
(Fig. 4B, right). Here, the wound closing effect of HGF was partially
blocked by a high concentration of G2 and by the G2-PEG-NPs.
Despite inducing Met phosphorylation, the anti-Met NANAPs do
inhibit cell scattering and thereby wound healing in A549 cells.
3.6. Internalization, lysosomal sorting and degradation of Met and
G2-PEG-NP
Eventually, anti-Met NANAPs could function as a nanocarrier for
the intracellular delivery of therapeutic agents. We therefore
assessed whether the G2-PEG-NPs were internalized by Met-
expressing cells using confocal ﬂuorescence microscopy. After 2 h
of incubation, speciﬁc uptake of only the G2-PEG-NP could be
observed in both A549 and MKN45 cells, as indicated by an intra-
cellular endosomal staining pattern (Fig. 5A). Co-staining of the
cells with early endosomal marker EEA-1 showed that the inter-
nalized nanoparticles were localized in early endosomes, which is
apparent from the yellow color in the merged image with green-
labeled nanoparticles and red-labeled-EEA-1 (Fig. 5B). Neverthe-
less, not all G2-PEG-NP were located in early endosomes at this
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Fig. 6. Anti-Met NANAPs are degraded by lysosomes and induce receptor downregulation. A) A549 (top) and MKN45 (bottom) cells were incubated with Alexa488-conjugated G2-
PEG-NP for 16 h and ﬁxed for confocal ﬂuorescence imaging. Late endosomes and lysosomes were stained with Lysotracker-Red. B) MKN45 cells were pulsed for 2 h with IRDye800-
conjugated PEG-NP or G2-PEG-NP and chased for 16 h. Cells were lysed and free dye was separated from intact nanoparticles by electrophoresis. Degradation of G2-PEG-NP is
apparent as the appearance of free dye (green) at the bottom of the gel and was quantiﬁed using the Odyssey Infrared scanner (right panel). C) A549 cells or D) MKN45 cells were
incubated with IRDye800-conjugated G2-PEG-NP in the absence or presence of the inhibitors chloroquine (CQ) and Lactacystin (LC) after which the appearance of free dye was
quantiﬁed as in B. E, F) Met downregulation 48 h after treatment with HGF (50 ng/ml), G2 (100 nM), PEG-NP (0.5 mg/ml) and G2-PEG-NP (0.5 mg/ml) on E) A549 and F) MKN45 cells.
Error bars represent SEM where n ¼ 3.
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endocytic vesicles, in which cargo is rapidly transported to further
downstream compartments like sorting and late endosomes and
eventually lysosomes [30].
To investigate whether the nanoparticles were routed towards
late endosomes or lysosomes, co-localization of Alexa488-labeled
G2-PEG-NP with Lysotracker Red was studied in A549 and
MKN45 cells by confocal ﬂuorescence microscopy (Fig. 6A). After
16 h of incubation, the G2-PEG-NP co-localized almost completely
with lysotracker Red, indicating that these NANAPs indeed end up
in late-endosomal/lysosomal compartments. To check whether the
nanoparticles were also degraded, a pulse-chase experiment wasperformed with IRDye800-labeled G2-PEG-NP or PEG-NP. After
16 h, degradation of the nanoparticles was observed by SDS-PAGE,
which is apparent by the appearance of free IRDye800 at the bot-
tom of the gel (Fig. 6B). Only Met-targeted nanoparticles showed
signs of degradation, which is in good correlation with the speciﬁc
binding and internalization of the G2-PEG-NP mentioned above
(Fig. 5A).
In general, protein degradation in cells is mediated by the pro-
teasome complex and/or by the proteases in the endosomal/lyso-
somal system. Lysosomal degradation of Met plays an important
role in the ligand-induced negative feedback mechanism of Met
[15]. In addition, it has been reported that ligand-induced
R. Heukers et al. / Biomaterials 35 (2014) 601e610 609degradation of Met is also regulated by proteasomal degradation
[31]. To study the nature of the observed degradation of the
nanoparticles in more detail, we inhibited both lysosomal and
proteasomal degradation with either the lysosome inhibitor chlo-
roquine (CQ), and the proteasome inhibitor lactacystin (LC). In both
A549 and MKN45 cells, co-incubation with 10 mM of CQ for 16 h
blocked the degradation of the G2-PEG-NP almost completely
(Fig. 6CeD). In contrast, LC had no effect on nanoparticle degra-
dation in A549 cells and a minor effect in MKN45 cells.
This lysosomal targeting makes the anti-Met NANAPs suitable
for the intracellular delivery and release of therapeutic compounds.
In addition, lysosomal trafﬁcking of Met induced by the NANAPs
could potentially lead to receptor downregulation in Met-
overexpressing tumors. This is particularly interesting for tumors
that highly overexpress Met and thereby induce constitutive acti-
vation of the receptor, as is the case with the MKN45 cell line
(Fig. S3). To investigate whether lysosomal degradation of G2-PEG-
NP is accompanied by receptor degradation, cells were incubated
with G2, PEG-NP, G2-PEG-NP and HGF for 48 h after which total
Met protein levels were determined by western blotting (Fig. 6Ee
F). While HGF most prominently induced Met downregulation in
A549 cells, treatment with G2-PEG-NP down regulated total Met
protein in both A549 and MKN45 cells. All together, these data
indicate that anti-Met NANAPs are primarily translocated to late
endosomes and lysosomes, which eventually results in lysosomal
degradation of both the nanoparticles and Met receptors.
4. Discussion
Met overexpression is correlated with poor prognosis in most of
the aggressive cancers, such as brain, liver, pancreatic cancers and
gastric carcinoma [8]. Targeted delivery of small-molecule drugs
can contribute to selective inhibition or even killing of Met-
expressing tumor cells. In this study, we performed phage display
selections for nanobodies speciﬁcally binding to human Met, and
evaluated the applicability of an anti-Met nanobody for targeting
albumin nanoparticles to Met-expressing tumor cells. Several anti-
Met nanobodies were obtained that were speciﬁcally binding to
Met with high afﬁnity. Besides binding Met, the selected nano-
bodies could compete for HGF binding to recombinant Met ecto-
domain. However, this competition was not observed on cells.
Although the contrast between these observations is quite evident,
it might be explained by a mechanistic difference between binding
of HGF to isolated and cellular Met. HGF binding to Met occurs via
two interaction sites, the SEMA domain and the immunoglobulin-
like region of Met [37,38]. Binding of HGF to the SEMA domain is
considered to induce a conformational change of the ectodomain,
revealing the second binding position on the Ig-like regions.
Possibly, the interaction of the radiolabeled HGF and the coated
recombinant ectodomain only involves one of these binding do-
mains and therefore the binding of HGF could easily be disrupted
by the selected nanobodies. Moreover, the binding of HGF toMet on
cells is considered to be further stabilized by secondary interactions
of HGF with heparin sulphate, which is present on the plasma
membrane [28]. The fact that G2-PEG-NPs did not compete with
HGF on cells also suggest that the potential therapeutic effects of
the NANAP’s in vivo would be independent of HGF levels.
The anti-Met nanobody was efﬁciently conjugated to the albu-
min nanoparticles, which allowed their speciﬁc binding to Met-
expressing tumor cells. A disadvantage of the nanobody is the
possible effect of the conjugation of a chemical compound as SATA
on the afﬁnity. This is especially the casewhen the site of interaction
is located in one of the CDR regions of the nanobody. We have
recently shown that by introducing an additional cysteine at the C-
terminus of a nanobody and using this for site-directed conjugation,effects on binding afﬁnity can be avoided [36]. Here, the effect of
SATA modiﬁcation on the binding afﬁnity of the selected anti-Met
nanobodies was tested and revealed only a small effect for only
one of the nanobodies. This indicates that the SATA groups probably
do not bind to a lysine present in the antigen-binding region.
Previously, similar nanoparticles were used to retarget toxins
like doxorubicin and ﬂuorescent dyes like Cy5 using whole anti-
bodies or peptides directed against avb3-integrins, the chemokine
receptor 4 (CXCR4), or somatostatin receptors [32e34]. Recently, Lu
et al. reported the selection of anti-Met single chain antibodies
(scFv) that were used for targeting of quantum dots or doxorubicin
loaded liposomes [35]. The afﬁnity of the reported scFv’s was
studied on isolated Met and was about 10-fold less than our anti-
Met nanobodies, which were tested on Met-positive cells. The af-
ﬁnity of the G2-nanobody was in the low nanomolar range, which
explains the efﬁcient binding of the G2-PEG-NP to the Met-
expressing cells.
The agonistic activity of G2-PEG-NP is possibly induced by re-
ceptor clustering via the multivalent anti-Met format of the nano-
particles. The fact that this was insufﬁcient to induce cell migration,
suggests that the NANAPs were unable to fully activate all down-
stream pathways of Met towards migration. Similar differential
downstream signaling towards cell motility, invasion and prolifer-
ation was observed with different agonistic antibodies against Met
[39]. Possibly, the nanoparticles and antibodies induce only a minor
activation of Met, which is insufﬁcient to activate downstream
pathways. A recent study with oral squamous carcinoma cells
showed that, despite a clear phosphorylation of Met, scratch
wound healing occurred dose-dependently and only above a
certain threshold concentration of HGF (no wound healing at
3.7 ng/ml of HGF to a clear healing at 33 ng/ml) [40]. These data
suggest the existence of a threshold of Met activation requires for
the full range of biological responses. Since Met activation by either
G2 or G2-PEG-NP did not result in a cellular response like cell
migration, we consider their agonistic properties to be of little
consequence for future use of the nanoparticles.
In general, the internalization of drug loaded and targeted
nanocarriers greatly enhances the speciﬁc killing of the targeted
cells [12,41,42]. The efﬁcacy of antibodies or nanoparticles can be
enhanced by employing receptor-mediated uptake. We have pre-
viously shown that internalizing liposomes decorated with anti-
EGFR nanobodies reduced total EGFR protein expression and
inhibited cell growth more potently than a nanobody alone [19].
The nanoparticles in this study also internalized and were subse-
quently targeted to lysosomes where they were degraded. Inter-
nalization of these complexes might be initiated by complex
formation of Met as previously suggested by the induced inter-
nalization of EGFR using anti-EGFR nanobodies bound to liposomes
[19]. The anti-EGFR liposomes did not stimulate tyrosine kinase
activity of EGFR, which is in contrast to the G2-PEG-NPs. While this
activation did not result in cell scattering, it resulted in Met re-
ceptor and eventually downregulation. This reduces the over-
activation of this pathway, which could potentially contribute to
the inhibition of tumor growth as we previously have shown for the
EGFR [19]. In a study by Petrelli et al., Met downregulation was
shown to reduce tumor size regardless of receptor phosphorylation
[43]. As such, the G2-PEG-NP could therefore have an intrinsic anti-
tumor activity, as observed in the scratch wound assay (Fig. S2),
where G2-PEG-NPs inhibited wound healing in A549 cells.
5. Conclusion
We have generated nanobodies speciﬁcally binding to Met,
which were used to target human albumin nanoparticles to Met-
expressing cells. The anti-Met NANAPs are internalized by Met-
R. Heukers et al. / Biomaterials 35 (2014) 601e610610expressing cells and transported to lysosomes for degradation of
both NANAPs and receptor. We conclude that the nanoparticles as
designed and characterized in this paper are a good candidate for
the selective delivery of chemotherapeutic drugs in the treatment
of Met overexpressing tumors.Acknowledgements
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